PacingCure aims to develop a novel gene therapy medicinal product (GTMP) to cure life-threatening cardiac pacing dysfunction by restoring the heart rate to the physiological range.

Our approach exhibits long-term effects and can be administered via a minimally invasive procedure.

In the TRACTION project, PacingCure – together with Amsterdam University Medical Center – will further optimize and validate AAV-mediated gene therapy by controlling transcription factor overexpression. This advancement enhances therapeutic effectiveness, thereby tackling pressing unmet medical needs and extends the enduring quality of life for severely affected patients.